ACRS — Aclaris Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00
- $84.90m
- -$26.19m
- $31.25m
- 28
- 43
- 29
- 25
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 75 | 54.1 | 191 | 218 | 119 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.704 | 0.772 | 0.623 | 0.484 | 0.298 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 83.8 | 57.5 | 205 | 232 | 129 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 7.2 | 5.78 | 4.77 | 3.78 | 5.48 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 98.3 | 70.8 | 251 | 255 | 197 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 22.4 | 14.9 | 22.9 | 21.9 | 31 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Liabilities | 28.4 | 33.1 | 53.9 | 57 | 40.2 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 69.9 | 37.6 | 197 | 198 | 157 |
Total Liabilities & Shareholders' Equity | 98.3 | 70.8 | 251 | 255 | 197 |
Total Common Shares Outstanding |